Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

meetings.asco.org

Thrombocytopenic myelofibrosis (MF) patients previously treated with a JAK inhibitor in a phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) [MOMENTUM].DetailsClinical Trial Registration NumberNCT04173494CitationJ Clin Oncol 40, 2022 (suppl 16; abstr 7061) You must be logged in and have a current registration to access this session's video and slides. If you think you should have...

  • 123456 Profile photo of Madelyn

    This abstract shows improvement in transfusion and spleen response with momelotinib in patients with thrombocytopenic myelofibrosis who had prior exposure to JAK inhibitors. Momelotinib was compared to Danazol and had similar toxicities.